FDA Implements New Regulatory Framework for Lab-Developed Tests After Years of Debate

FDA Implements New Regulatory Framework for Lab-Developed Tests After Years of Debate

By Helen Whitaker

The U.S. Food and Drug Administration published its final rule on May 6, 2024, ending enforcement discretion for most laboratory-developed tests (LDTs) and subjecting them to medical device regulation under the Federal Food, Drug, and Cosmetic Act [1][3]. LDTs are defined as in vitro diagnostic products that are intended for clinical use and designed, manufactured and used within a single laboratory [2]. The rule introduces a four-year phased implementation requiring registration, listing, labeling standards, adverse event reporting, quality system compliance, and premarket review for higher-risk tests [4].

What this means

The finalized oversight framework aligns LDT regulation with the framework already applied to other in vitro diagnostics. Laboratories will be required to meet staged compliance obligations that escalate from basic registration and listing to full quality system requirements and, for certain higher-risk tests, premarket review. The FDA has stated that these measures support analytic and clinical validity, safety, and effectiveness of diagnostic tests while allowing a four-year period for adaptation [3][4]. Long-term effects on test innovation, laboratory operations, and the availability of specific tests remain uncertain pending implementation and further guidance.

What Exactly Are Laboratory-Developed Tests (LDTs)?

Laboratory-developed tests are in vitro diagnostic products intended for clinical use and designed, manufactured and used within a single laboratory [2]. These tests have historically operated under enforcement discretion, meaning the FDA generally declined to enforce applicable medical device regulatory requirements for most LDTs [3]. The final rule ends that discretion for the majority of LDTs, classifying them as medical devices subject to the Federal Food, Drug, and Cosmetic Act [1].

Why Has the FDA Moved to End Enforcement Discretion for LDTs at This Time?

The FDA has determined that LDTs are medical devices subject to the FD&C Act and that most will no longer receive enforcement discretion [3]. Agency statements indicate that increased oversight is necessary to assure analytic and clinical validity, safety, and effectiveness of diagnostic tests used in clinical decision-making [3]. The final rule, published after years of debate, aligns LDT oversight more closely with that of other in vitro diagnostics already regulated by the FDA [1][4].

What Is the Four-Year Phased Implementation Timeline and Associated Requirements?

The final rule establishes a four-year phased implementation period with staged compliance requirements [4]. Compliance begins with facility registration and listing in the first year, then progresses to additional obligations including medical device reporting, labeling standards, and quality system regulation under 21 CFR 820 [1]. By the fourth year, premarket review requirements apply to higher-risk tests through established pathways such as 510(k), premarket approval (PMA), or De Novo classification [4]. The rule was published on May 6, 2024, and becomes effective on July 5, 2024 [1].

How Will the Rule Affect Clinical Laboratories, Test Availability, and Patients?

Clinical laboratories will face new compliance obligations that vary according to test risk level and the phased timeline [4]. The FDA has noted that the phased approach balances patient access to innovative testing with stronger regulatory controls [3]. The agency expects the framework to support greater assurance of test safety and effectiveness for patients while certain exceptions, such as tests addressing unmet public health needs, may continue to receive modified oversight [1][4].

What Compliance Obligations Will Laboratories Face Under the New Framework?

Laboratories will be required to register their facilities, list their tests, comply with labeling requirements, report adverse events, implement quality systems consistent with 21 CFR 820, and, for applicable tests, obtain premarket clearance, approval, or De Novo authorization [1][4]. These obligations apply to LDTs that no longer qualify for enforcement discretion [3]. Specific guidance documents detailing application of certain provisions are still under development [4].

Limitations

Specific FDA guidance documents on how certain provisions will be applied are still under development. Potential legal challenges or Congressional action could alter implementation. Long-term effects on test innovation and laboratory consolidation remain uncertain and will require ongoing monitoring.